Humacyte, Inc. (NASDAQ:HUMA) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Consensus "Moderate Buy": Eight analysts give HUMA a consensus rating of "Moderate Buy" (7 buys, 1 sell) with an average 12‑month price target of $7.7143 versus a recent share price near $0.86 and a market cap of about $190M.
• Wide analyst divergence: Analyst views vary sharply—from downgrades to "strong sell" and low targets like $3 up to a $25 target—reflecting significant disagreement on the company's prospects.
• Weak near‑term fundamentals: Humacyte is a clinical‑stage biotech whose latest quarter matched EPS at ($0.13) but missed revenue ($0.47M vs. $1.35M), has negative ROE/net margin, a 12‑month range of $0.55–$2.93, and roughly 44.7% institutional ownership (notably larger stake added by UBS).

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $7.7143.

A number of equities analysts have commented on the stock. Wall Street Zen cut shares of Humacyte from a "sell" rating to a "strong sell" rating in a research note on Saturday, April 11th. BTIG Research restated a "buy" rating and set a $3.00 price objective on shares of Humacyte in a research report on Tuesday, April 28th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Humacyte in a report on Friday, April 10th. Benchmark cut their target price on shares of Humacyte from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, January 21st. Finally, D. Boral Capital restated a "buy" rating and set a $25.00 price target on shares of Humacyte in a research report on Tuesday, April 28th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of HUMA. Caitong International Asset Management Co. Ltd increased its stake in shares of Humacyte by 841.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 70,414 shares of the company's stock worth $68,000 after acquiring an additional 62,931 shares in the last quarter. Aristides Capital LLC bought a new stake in Humacyte during the fourth quarter worth about $156,000. Fisher Asset Management LLC bought a new stake in Humacyte during the fourth quarter worth about $47,000. UBS Group AG grew its holdings in Humacyte by 48.8% in the fourth quarter. UBS Group AG now owns 2,978,610 shares of the company's stock worth $2,862,000 after purchasing an additional 976,275 shares during the period. Finally, R Squared Ltd purchased a new stake in Humacyte in the fourth quarter worth about $25,000. 44.71% of the stock is owned by institutional investors.

Humacyte Stock Performance

NASDAQ HUMA opened at $0.86 on Friday. The firm has a market cap of $189.89 million, a P/E ratio of -4.28 and a beta of 2.31. The company has a quick ratio of 2.95, a current ratio of 3.69 and a debt-to-equity ratio of 20.08. The company's 50 day moving average is $0.88 and its 200-day moving average is $1.11. Humacyte has a 12-month low of $0.55 and a 12-month high of $2.93.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its earnings results on Friday, March 27th. The company reported ($0.13) EPS for the quarter, hitting the consensus estimate of ($0.13). Humacyte had a negative return on equity of 990.48% and a negative net margin of 1,998.87%.The business had revenue of $0.47 million during the quarter, compared to the consensus estimate of $1.35 million. Sell-side analysts predict that Humacyte will post -0.39 earnings per share for the current year.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company's proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient's own tissue. Humacyte's primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company's lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.